Fragile X Syndrome Drug Validation Initiative (FRAX-DVI)

Fragile X Syndrome Drug Validation Initiative (FRAX-DVI)

The FRAXA Drug Validation Initiative (FRAX-DVI) provides speedy, cost-effective, objective testing of potential new fragile X treatments. FRAXA has funded FRAX-DVI for $50,000 in 2017.

Read more